CEO Of SFDA Engages With US Academic Institutions To Enhance Scientific Cooperation

Dr. Hisham Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), engaged with U.S. scientific and academic leaders during the 41st annual International Society for Pharmacoepidemiology (ISPE) meeting. These discussions aimed to boost cooperation and share expertise, enhancing SFDA's scientific and regulatory influence.

At Johns Hopkins University, Dr. Aljadhey met with Professor Keisha Porter, dean of the Bloomberg School of Public Health, along with faculty members. They explored the school's advanced clinical study experiences and the use of modern technologies to support drug safety. The role of artificial intelligence in regulatory sciences was also highlighted.

Dr. Aljadhey also visited George Washington University, where he met Professor Kathryn Newcomer, director of the Trachtenberg School of Public Policy and Public Administration. Their discussion covered public policy challenges and issues related to health, pharmaceuticals, and food systems. This meeting opened new avenues for academic collaboration.

The SFDA CEO emphasized the importance of partnerships with academic institutions, stating that regulatory decisions are grounded in robust scientific research. He noted that these efforts align with Saudi Vision 2030's Health Sector Transformation Program, which seeks to create a more efficient healthcare system.

The meetings underscored SFDA's commitment to innovation by integrating modern technologies into its operations. By collaborating with leading academic institutions, SFDA aims to enhance its regulatory framework through cutting-edge research and studies.

Dr. Aljadhey's engagements reflect SFDA's dedication to improving healthcare standards in Saudi Arabia by leveraging international expertise. These collaborations are crucial for developing a forward-thinking healthcare system that meets global standards.

With inputs from SPA